Coya Therapeutics, Inc. (COYA) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-12

Key Insights

FDA granted Fast Track Designation to COYA 302 for ALS treatment on May 11, 2026, which accelerates the development and review timeline and signals regulatory confidence in the therapeutic approach.
Q1 2026 financial results were disclosed via press release, though specific financial metrics are not detailed in the 8-K filing itself, limiting ability to assess operational performance.
Coya Therapeutics maintains emerging growth company status, allowing for reduced disclosure and compliance requirements that may provide flexibility but also limit transparency for investors.

Want the newest filings?

This analysis covers the filing from 2026-05-12. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-12

Coya Therapeutics established a $30 million at-the-market (ATM) equity offering with Leerink Partners, providing flexible capital access without immediate dilution obligations, suggesting the company is preserving cash while maintaining fundraising optionality.
The 3.0% commission structure to Leerink Partners is competitive for ATM offerings and reflects standard market terms, though the company bears all offering expenses and provides indemnification, typical for emerging growth companies seeking capital.
As an emerging growth company, Coya retains regulatory flexibility under scaled disclosure requirements, and the shelf registration on Form S-3 indicates the SEC previously qualified the company for efficient capital raising, suggesting prior compliance success.

Filed: 2026-01-30

Coya Therapeutics raised approximately $11.1 million in a private placement from key investors Dr. Reddy's Labs and Greenlight Capital.
The company plans to use the proceeds to tech transfer, scale up manufacturing, and accelerate programs for its lead candidate COYA 302.
Coya Therapeutics reiterated its cash runway guidance into the second half of 2027, extending past the projected topline readout for its ALSTARS trial.

Filed: 2026-01-20

Coya Therapeutics reported a strong cash balance of $46.8 million as of December 31, 2025, which provides a projected cash runway into the second half of 2027.
The company expects to report topline data readout from its ALSTARS Phase 2 trial in the first quarter of 2027, a key milestone for the company's pipeline.
As an emerging growth company, Coya Therapeutics may choose to take advantage of the extended transition period for complying with new or revised financial accounting standards.

Filed: 2026-01-08

Coya Therapeutics, an emerging biotech company, reported positive results from a proof-of-concept study evaluating a combination therapy of low-dose IL-2 and CTLA4-Ig in 9 patients with Frontotemporal Dementia (FTD). The study demonstrated increased Treg numbers and function, as well as cognitive function stability, over the 22-week treatment period.
The safety profile of the combination therapy was favorable, with the most common adverse event being mild erythema at the injection site, and no serious adverse events reported.
The stable cognitive function, as measured by MOCA and CDR-FTLD scores, suggests the potential of this combination therapy to slow the progression of cognitive decline in FTD patients, an important unmet medical need.

Other reports for Coya Therapeutics, Inc.

Quarterly Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.